Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Heparin Utan Konserveringsmedel

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Heparin Testmiljö

Heparin

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998;21:71-8.

  2. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-8.

  3. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.

  4. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196-203.

  5. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-16.

  6. HEPARIN SODIUM injection (heparin sodium). DailyMed [www]. US National Library of Medicine. [updated 2018-08-01, cited 2019-02-19].

  7. Asgar A, Chandrasekhar J, Mikhail G, Webb J, Lefèvre T, Tamburino C et al. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial. Catheter Cardiovasc Interv. 2017;89(1):144-153.

  8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937-41.

  9. Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todoli JA, Jiménez-Gil M, Di Micco P et al. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2011;9:1761-8.

  10. Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther. 2009;27:77-82.

  11. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998;21:71-8.
  2. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-8.
  3. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.
  4. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM et al. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009;103:1196-203.
  5. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-16.
  6. HEPARIN SODIUM injection (heparin sodium). DailyMed [www]. US National Library of Medicine. [updated 2018-08-01, cited 2019-02-19].
  7. Asgar A, Chandrasekhar J, Mikhail G, Webb J, Lefèvre T, Tamburino C et al. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial. Catheter Cardiovasc Interv. 2017;89(1):144-153.
  8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937-41.
  9. Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todoli JA, Jiménez-Gil M, Di Micco P et al. Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2011;9:1761-8.
  10. Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther. 2009;27:77-82.
  11. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]